MX348184B - Métodos y composiciones para tratar diarrea asociada con vih. - Google Patents

Métodos y composiciones para tratar diarrea asociada con vih.

Info

Publication number
MX348184B
MX348184B MX2013004873A MX2013004873A MX348184B MX 348184 B MX348184 B MX 348184B MX 2013004873 A MX2013004873 A MX 2013004873A MX 2013004873 A MX2013004873 A MX 2013004873A MX 348184 B MX348184 B MX 348184B
Authority
MX
Mexico
Prior art keywords
diarrhea
methods
compositions
treating hiv
associated diarrhea
Prior art date
Application number
MX2013004873A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004873A (es
Inventor
Forbes William
Bortey Enoch
King Steven
Chaturvedi Pravin
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348184(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of MX2013004873A publication Critical patent/MX2013004873A/es
Publication of MX348184B publication Critical patent/MX348184B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2013004873A 2010-10-31 2011-10-31 Métodos y composiciones para tratar diarrea asociada con vih. MX348184B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US40933510P 2010-11-02 2010-11-02
US41624910P 2010-11-22 2010-11-22
US201161434379P 2011-01-19 2011-01-19
PCT/US2011/058549 WO2012058664A1 (en) 2010-10-31 2011-10-31 Methods and compositions for treating hiv-associated diarrhea

Publications (2)

Publication Number Publication Date
MX2013004873A MX2013004873A (es) 2013-08-21
MX348184B true MX348184B (es) 2017-06-02

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004873A MX348184B (es) 2010-10-31 2011-10-31 Métodos y composiciones para tratar diarrea asociada con vih.

Country Status (20)

Country Link
US (4) US8962680B2 (enExample)
EP (1) EP2632550B1 (enExample)
JP (2) JP6063385B2 (enExample)
CN (2) CN103370101A (enExample)
AU (1) AU2011320155B2 (enExample)
BR (1) BR112013010774A2 (enExample)
CA (1) CA2816416C (enExample)
DK (1) DK2632550T3 (enExample)
EC (1) ECSP13012650A (enExample)
ES (1) ES2635435T3 (enExample)
HK (1) HK1249036A1 (enExample)
HU (1) HUE035393T2 (enExample)
MX (1) MX348184B (enExample)
PE (1) PE20140036A1 (enExample)
PH (1) PH12013500857A1 (enExample)
PL (1) PL2632550T3 (enExample)
PT (1) PT2632550T (enExample)
RU (1) RU2597746C2 (enExample)
WO (1) WO2012058664A1 (enExample)
ZA (1) ZA201303136B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG161259A1 (en) 2006-05-01 2010-05-27 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
AU2007248183B2 (en) * 2006-05-01 2013-08-01 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
CA2816416C (en) 2010-10-31 2020-02-11 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
CA2893070A1 (en) * 2012-12-07 2014-06-12 Salix Pharmaceuticals, Ltd Methods and compositions for treating hiv-associated diarrhea
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
JOP20220339A1 (ar) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
WO2000047062A2 (en) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
WO2005074575A2 (en) * 2004-01-30 2005-08-18 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007002173A1 (en) * 2005-06-22 2007-01-04 University Of Massachusetts Hiv-1 protease inhibitors, and methods of making and using them
JP2009524585A (ja) 2005-12-15 2009-07-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
AU2007248183B2 (en) 2006-05-01 2013-08-01 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
SG161259A1 (en) 2006-05-01 2010-05-27 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EA023814B1 (ru) 2009-08-26 2016-07-29 Гленмарк Фармасьютикалс Лтд. Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
US20120202876A1 (en) 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
CA2816416C (en) 2010-10-31 2020-02-11 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
RU2593014C2 (ru) 2011-01-27 2016-07-27 Гленмарк Фармасьютикалс Лимитед Способ производства проантоцианидиновой полимерной композиции
RU2014124981A (ru) 2011-12-22 2016-02-10 Гленмарк Фармасьютикалс Лимитед Неэнтеросолюбильная фармацевтическая композиция, содержащая крофелемер
CA2893070A1 (en) 2012-12-07 2014-06-12 Salix Pharmaceuticals, Ltd Methods and compositions for treating hiv-associated diarrhea

Also Published As

Publication number Publication date
EP2632550B1 (en) 2017-05-03
AU2011320155B2 (en) 2016-02-25
RU2597746C2 (ru) 2016-09-20
US8962680B2 (en) 2015-02-24
AU2011320155A1 (en) 2013-05-09
JP6310971B2 (ja) 2018-04-11
HUE035393T2 (en) 2018-05-02
US20150190367A1 (en) 2015-07-09
PT2632550T (pt) 2017-08-02
EP2632550A4 (en) 2014-04-23
DK2632550T3 (en) 2017-08-07
CA2816416A1 (en) 2012-05-03
WO2012058664A1 (en) 2012-05-03
ES2635435T3 (es) 2017-10-03
JP2013540826A (ja) 2013-11-07
PL2632550T3 (pl) 2017-10-31
RU2013123794A (ru) 2014-12-10
EP2632550A1 (en) 2013-09-04
MX2013004873A (es) 2013-08-21
US20140294903A1 (en) 2014-10-02
BR112013010774A2 (pt) 2017-03-21
US9585868B2 (en) 2017-03-07
CN103370101A (zh) 2013-10-23
ECSP13012650A (es) 2013-10-31
PH12013500857A1 (en) 2018-01-17
CN107595836A (zh) 2018-01-19
US20120107370A1 (en) 2012-05-03
CA2816416C (en) 2020-02-11
US20120184605A1 (en) 2012-07-19
PE20140036A1 (es) 2014-01-31
ZA201303136B (en) 2016-01-27
JP2017019806A (ja) 2017-01-26
JP6063385B2 (ja) 2017-01-18
HK1249036A1 (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
MX348184B (es) Métodos y composiciones para tratar diarrea asociada con vih.
MX382400B (es) Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea.
ECSP15030799A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
MX2021005172A (es) Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir el transporte de fosfato.
ECSP13012551A (es) Terapia de combinación para tratar infección por hcv.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
MX2015007065A (es) Metodo y composiciones para tratar diarrea asociada con vih.
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
CO6670518A2 (es) Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos
MX2014003873A (es) Metodo para tratar el carcinoma mucoepidermoide.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
CO6771411A2 (es) Metodos y composiciones para tratar diarrea asociada al vih
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2022016367A (es) Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
GT201400071A (es) Combinación terapéutica para el tratamiento de cáncer
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
CL2022003634A1 (es) Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
CL2024003535A1 (es) Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NAPO PHARMACEUTICALS, INC.

FG Grant or registration